Literature DB >> 25276651

Disulfiram Implantation for the Treatment of Alcoholism: Clinical Experiences from the Plastic Surgeon's Point of View.

Billur Sezgin1, Serhat Sibar2, Hakan Bulam3, Kemal Findikcioglu2, Serhan Tuncer2, Bilge Dogan4.   

Abstract

BACKGROUND: Disulfiram implantation is a widely used treatment alternative for alcohol abuse, yet reports on the surgical aspect of disulfiram implantation with respect to patient and drug-related treatment efficacy and wound complications are very limited. We present our clinical experiences with disulfiram implantation and discuss the surgical outcomes obtained with different anatomical planes for implantation.
METHODS: Medical records of all patients referred to our clinic from the psychiatry department between 2007 and 2013 for disulfiram implantation were retrospectively analyzed. Implantation was carried out using 10 sterile Disulfiram tablets (WZF Polfa S.A.), each tablet containing 100 mg of disulfiram. The procedure was carried out by implanting the tablets randomly in either a subcutaneous or an intramuscular plane. The location and the plane of implantation and the complications were recorded for each patient and compared to determine the differences in the outcomes.
RESULTS: A total of 32 implantation procedures were evaluated for this study. Twenty-five implants were placed in the intramuscular plane (78.2%), while seven implants were placed subcutaneously (21.8%). Exposure was encountered in three of the seven subcutaneous implants (42.9%), while no exposure was seen with the intramuscular implants. Incomplete absorption of the tablets was encountered in one patient with a previous subcutaneous implant who presented 1 year later for re-implantation as part of the continuation of therapy.
CONCLUSIONS: To overcome the issue of treatment continuation in the case of disulfiram therapy, which may be ceased due to frequently encountered wound complications, we believe that implantation in the subscapular intramuscular plane allows both uneventful healing and an out-of-reach implant location.

Entities:  

Keywords:  Alcoholism; Bioabsorbable implant; Disulfiram

Year:  2014        PMID: 25276651      PMCID: PMC4179363          DOI: 10.5999/aps.2014.41.5.571

Source DB:  PubMed          Journal:  Arch Plast Surg        ISSN: 2234-6163


  11 in total

Review 1.  Techniques to enhance compliance with disulfiram.

Authors:  J P Allen; R Z Litten
Journal:  Alcohol Clin Exp Res       Date:  1992-12       Impact factor: 3.455

2.  Treatment of alcoholism with a sensitizing drug.

Authors:  O MARTENSEN-LARSEN
Journal:  Lancet       Date:  1948-12-25       Impact factor: 79.321

3.  A drug sensitizing the organism to ethyl alcohol.

Authors:  J HALD; E JACOBSEN
Journal:  Lancet       Date:  1948-12-25       Impact factor: 79.321

4.  Disulfiram implantation for alcoholism.

Authors:  A M Kellam; J M Wesolkowski
Journal:  Lancet       Date:  1968-04-27       Impact factor: 79.321

5.  The use of disulfiram implantation in alcoholism.

Authors:  M T Malcolm; J S Madden
Journal:  Br J Psychiatry       Date:  1973-07       Impact factor: 9.319

6.  A double-blind placebo controlled study of male alcoholics given a subcutaneous disulfiram implantation.

Authors:  J Johnsen; A Stowell; J E Bache-Wiig; T Stensrud; A Ripel; J Mørland
Journal:  Br J Addict       Date:  1987-06

7.  Disulfiram implantation: placebo, psychological deterrent, and pharmacological deterrent effects.

Authors:  A Wilson; W J Davidson; J White
Journal:  Br J Psychiatry       Date:  1976-09       Impact factor: 9.319

Review 8.  A review of the pharmacokinetics and pharmacodynamics of disulfiram and its metabolites.

Authors:  B Johansson
Journal:  Acta Psychiatr Scand Suppl       Date:  1992

9.  Disulfiram implant: a double-blind placebo controlled follow-up on treatment outcome.

Authors:  J Johnsen; J Mørland
Journal:  Alcohol Clin Exp Res       Date:  1991-06       Impact factor: 3.455

10.  Subcutaneous testosterone pellet implant (Testopel) therapy for men with testosterone deficiency syndrome: a single-site retrospective safety analysis.

Authors:  Richard K Cavender; Melissa Fairall
Journal:  J Sex Med       Date:  2009-09-29       Impact factor: 3.802

View more
  1 in total

1.  Identification of disulfiram as a secretase-modulating compound with beneficial effects on Alzheimer's disease hallmarks.

Authors:  Sven Reinhardt; Nicolai Stoye; Mathias Luderer; Falk Kiefer; Ulrich Schmitt; Klaus Lieb; Kristina Endres
Journal:  Sci Rep       Date:  2018-01-22       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.